**Supplemental Appendix**

**List of investigators**

Kenichi Todo, MD1,2; Nobuyuki Sakai, MD1; Hirotoshi Imamura, MD1; Hiroshi Yamagami, MD1,3; Hidemitsu Adachi, MD1; Tomoyuki Kono, MD1; Junya Kobayashi, MD1,4; Shiro Yamamoto, MD1,5; Takeshi Morimoto, MD6; Shoichi Tani, MD1; Michi Kawamoto, MD1; Manabu Sakaguchi, MD1,2; Yasushi Ueno, MD1,7; Takeharu Kunieda, MD1,8; Osamu Narumi, MD1,9; Chiaki Sakai, MD1; Akira Ishii, MD1,10; Taku Hoshi, MD1,11; Masaomi Koyanagi, MD1,9; Yohei Mineharu, MD1,10; Tatsuya Ishikawa, MD1,12; Yoji Kuramoto, MD1,13; Shinsuke Sato, MD1,14; Nobuyuki Ohara, MD1,4; Koichi Arimura, MD1,15; Hajime Nakamura, MD2; Takeo Nishida, MD2; Yasufumi Gon, MD2; Toshiyuki Fujinaka, MD2,16; Kazuhisa Yoshiya, MD2; Takeshi Shimazu, MD2; Haruhiko Kishima MD2; Hideki Mochizuki, MD2; Nobuo Kohara, MD1, Haruhiko Kikuchi, MD1; So Tokunaga, MD1; Tomonari Saito, MD1,17; Takayuki Funatsu, MD1; Hiroyuki Ikeda, MD1,10; Mikiya Beppu, MD1,13; Ryuichiro Kajikawa, MD1,18; Kazuto Kobayashi, MD1,19; Yoshihiko Ioroi, MD1,9; Taichiro Imahori, MD1,20; Junya Shibata, MD1,21; Tomoyoshi Shigematsu, MD1,2; Hideo Chihara, MD1,22; Katsunori Asai, MD1,2; Narihide Shinoda MD1,7; Yoshiko Matsuda MD1,10; Taku Inada, MD1,10; Takenori Ogura MD1,10; Teishiki Shibata, MD1,23; Takaaki Morimoto, MD1, 10; Yuji Agawa, MD1,10; Kampei Shimizu, MD1,10; Noriyoshi Takebe, MD1,10; Sho Murase, MD1,2; Kyoko Higashida, MD1,2; Keita Suzuki, MD1; Hiromasa Adachi, MD1; Tomohiro Okuda, MD1,15; Yuichi Matsui, MD1; Yasunori Yoshida, MD1,13; Shuhei Kawabata, MD1; Yasutaka Murakami, MD1,4; Kazuyuki Mikami MD1; Ryo Akiyama, MD1; Kazufumi Horiuchi, MD1; Hajime Yoshimura, MD1; Minako Beppu1, 24, MD; Kosuke Yoshida, MD1, 25; Norifumi Sugo, MD1, 26; Hiroaki Sekiya, MD1, 27; Junko Ishii, MD1; Yoshitaka Tamaki, MD1, 28; Masaya Togo, MD1, 28; Tetsuhiro Ueda, MD1, 29; Satoru Fujiwara, MD1; Jun Ueda, MD1; Junichiro Ohira, MD1; Naoya Mikami, MD1; Toshiaki Goda, MD4; Takeshi Ikegami, MD4, 5; Kotaro Watanabe, MD2, 4; Akihiro Watanabe, MD2, 4; Daisuke Takahashi, MD4; BooHan Hyun, MD5; Keiko Nagano, MD5; Kazuo Hashikawa, MD5

1Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Japan

2Stroke Center, Osaka University Graduate School of Medicine, Japan

3Department of Neurology, National Cerebral and Cardiovascular Center, Japan

4Department of Vascular Neurology, National Hospital Organization Osaka Minami Medical Center, Japan

5Division of Stroke Medicine, National Hospital Organization Osaka Medical Center, Japan

6Department of Clinical Epidemiology, Hyogo College of Medicine,

7Department of Neurosurgery, Shinko Hospital, Japan

8Department of Neurosurgery, Ehime University School of Medicine, Japan

9Department of Neurosurgery, National Hospital Organization Himeji Medical Center, Japan

10Department of Neurosurgery, Kyoto University Graduate School of Medicine, Japan

11Department of Neurology, Osaka General Medical Center, Japan

12Department of Neurosurgery, Tokyo Women's Medical University, Japan

13Department of Neurosurgery, Hyogo College of Medicine, Japan

14Department of Neurosurgery and Neurovascular therapy, St. Luke's International Hospital, Japan

15Department of Neurosurgery, Kyushu University Graduate School of Medical Sciences, Japan

16Deparment of Neurosurgery, National Hospital Organization Osaka Medical Center, Japan

17Dpartment of Neurology and Stroke Medicine, Tokyo Metropolitan Tama Medical Center, Japan

18Department of Neurosurgery, Osaka Neurological Institute, Japan.

19Department of Neuro-Endovascular Therapy, Ise Red-Cross Hospital, Japan

Department of Neurosurgery, Otsu City Hospital, Japan

20Department of Neurosurgery, Toyooka Hospital, Japan

21Department of Neurosurgery, Shizuoka Prefectural Hospital, Japan

22Department of Neurosurgery, Kokura Memorial Hospital, Japan

23Department of Neurosurgery, Nagoya City University Medical School, Japan

24Department of Neurology, Chiba University Graduate School of Medicine, Japan

25Department of Neurology, National Hospital Organization Asahikawa Medical Center, Japan

26Department of Neurology, Kobe City Medical Center West Hospital, Japan

27Department of Neurology, Kobe University Graduate School of Medicine, Japan.

28Department of Neurology, Kyoto University Graduate School of Medicine, Japan

29Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan

**Supplemental tables and figures**

Supplemental Table 1: Characteristics among follow-up methods

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **No follow-up****(N = 100)** | **Outpatient clinic****(N = 140)** | **Telephone****(N = 88)** | **Letter****(N = 75)** | ***P* value** |
| Age, median (IQR), y | 77 (69–82) | 71 (64–79) | 74 (67–81) | 78 (71–85) | < 0.01 |
| Male sex, No. (%) | 53 (53%) | 90 (64%) | 50 (57%) | 45 (60%) | 0.35 |
| Successful reperfusion, No. (%) | 55 (55%) | 106 (76%) | 31 (35%) | 55 (73%) | < 0.01 |
| mRS score of 0–2 at 90 days, No. (%) | 27 (27%) | 83 (59%) | 17 (19%) | 17 (23%) | < 0.01 |
| Data acquisition at one year, No. (%) | 0 (0%) | 140 (100%) | 81 (92%) | 47 (63%) | < 0.01 |

IQR indicates interquartile rage; and mRS, modified Rankin Scale.

Supplemental Table 2: Multivariate logistic regression models for improvement.

|  |  |  |
| --- | --- | --- |
|  | **Odds ratio****(95% Confidence Interval)** | ***P* value** |
| Age (/y) | 0.97 (0.95–1.00) | 0.05 |
| Atrial fibrillation | 0.80 (0.39–1.65) | 0.54 |
| Hypertension | 0.78 (0.38–1.61) | 0.50 |
| Diabetes mellitus | 1.31 (0.60–2.90) | 0.84 |
| NIHSS (/1 point) | 0.72 (0.45–1.18) | 0.20 |
| IV-rtPA therapy | 1.17 (0.54–2.52) | 0.69 |
| Successful reperfusion | 2.65 (1.23–5.73) | < 0.05 |
| PH2\* or SAH | 1.29 (0.47–3.53) | 0.62 |
| Recurrence | 0.27 (0.03–0.2.15) | 0.21 |
| mRS score at 90 days (/1 point) | 1.35 (1.05–1.73) | < 0.05 |

IV-rtPA indicates intravenous recombinant tissue plasminogen activator; mRS; modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Table 3: Multivariate logistic regression models for deterioration.

|  |  |  |
| --- | --- | --- |
|  | **Odds ratio****(95% Confidence Interval)** | ***P* value** |
| Age (/y) | 1.05 (1.01–1.08) | < 0.01 |
| Atrial fibrillation | 0.97 (0.53–1.78) | 0.93 |
| Hypertension | 1.02 (0.55–1.91) | 0.94 |
| Diabetes mellitus | 1.43 (0.75–2.74) | 0.28 |
| NIHSS (/1 point) | 1.79 (1.18–2.71) | < 0.01 |
| IV-rtPA therapy | 0.77 (0.40–1.49) | 0.44 |
| Successful reperfusion | 0.33 (0.18–0.62) | < 0.01 |
| PH2\* or SAH | 1.22 (0.51–2.90) | 0.65 |
| Recurrence | 4.88 (1.61–14.8) | < 0.01 |
| mRS score at 90 days (/1 point) | 0.85 (0.68–1.05) | 0.13 |

IV-rtPA indicates intravenous recombinant tissue plasminogen activator; mRS; modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Table 4: Multivariate logistic regression models for better mRS score at 1 year.

|  |  |  |
| --- | --- | --- |
|  | **Common odds ratio****(95% Confidence Interval)** | ***P* value** |
| Age (/y) | 0.98 (0.96–0.99) | < 0.05 |
| Atrial fibrillation | 0.92 (0.57–1.49) | 0.73 |
| Hypertension | 0.85 (0.52–1.38) | 0.51 |
| Diabetes mellitus | 1.00 (0.58–1.73) | 0.99 |
| NIHSS (/1 point) | 0.97 (0.94–0.99) | < 0.05 |
| IV-rtPA therapy | 1.00 (0.60–1.67) | 0.99 |
| Successful reperfusion | 2.08 (1.29–3.37) | < 0.01 |
| PH2\* or SAH | 1.04 (0.49–2.19) | 0.92 |
| Recurrence | 0.13 (0.04–0.40) | < 0.01 |
| mRS score at 90 days (/1 point) | 0.19 (0.14–0.24) | < 0.01 |

IV-rtPA indicates intravenous recombinant tissue plasminogen activator; mRS; modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Table 5: Clinical characteristics and 90-day mRS score of patients, with or without 1-year mRS data.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **With 1**–**year mRS data****(N = 268)** | **Without 1**–**year mRS data** **(N = 135)** | ***P* value** |
| Age, median (IQR), y | 73 (66–81) | 77 (68–83) | < 0.01 |
| Male sex, No. (%) | 164 (61%) | 74 (55%) | 0.22 |
| Vascular risk factors |  |  |  |
|  Atrial fibrillation, No. (%) | 144 (54%) | 90 (67%) | < 0.05 |
|  Hypertension, No. (%)  | 176 (66%) | 82 (61%) | 0.33 |
|  Diabetes mellitus, No. (%) | 65 (24%) | 41 (30%) | 0.19 |
| NIHSS score, median (IQR) | 17 (13–23) | 19 (15–26) | < 0.05 |
| IV-rtPA therapy, No. (%) | 71 (26%) | 38 (28%) | 0.72 |
| Successful reperfusion, No (%) | 167 (62%) | 80 (59%) | 0.55 |
| PH2\* or SAH, No. (%) | 30 (11%) | 19 (14%) | 0.40 |
| mRS score of 0–2 at 90 days, No. (%) | 114 (43%) | 30 (22%) | < 0.01 |
|  mRS score of 0 at 90 days, No. (%) | 29 (11%) | 6 (4%) |  |
|  mRS score of 1 at 90 days, No. (%) | 38 (14%) | 10 (7%) |  |
|  mRS score of 2 at 90 days, No. (%) | 47 (18%) | 14 (10%) |  |
|  mRS score of 3 at 90 days, No. (%) | 36 (13%) | 13 (10%) |  |
|  mRS score of 4 at 90 days, No. (%) | 64 (24%) | 53 (39%) |  |
|  mRS score of 5 at 90 days, No. (%) | 54 (20%) | 39 (29%) |  |
| Telephone interview, No. (%) | 81 (30%) | 7 (5%) | <0.01 |
| Letter survey, No. (%) | 47 (18%) | 28 (21%) | 0.44 |

IQR indicates interquartile rage; IV-rtPA, intravenous recombinant tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Table 6: Multiple imputation methods for improvement.

|  |  |  |
| --- | --- | --- |
|  | **Odds ratio****(95% Confidence Interval)** | ***P* value** |
| Age (/y) | 0.98 (0.95–1.01) | 0.13 |
| Atrial fibrillation | 0.74 (0.34–1.59) | 0.43 |
| Hypertension | 0.87 (0.46–1.67) | 0.68 |
| Diabetes mellitus | 1.03 (0.35–2.99) | 0.96 |
| NIHSS (/1 point) | 0.97 (0.92–1.02) | 0.18 |
| IV-rtPA therapy | 1.28 (0.53–3.11) | 0.58 |
| Successful reperfusion | 2.91 (1.39–6.08) | < 0.01 |
| PH2\* or SAH | 1.27 (0.42–3.85) | 0.67 |
| mRS score at 90 days (/1 point) | 1.33 (1.03–1.71) | < 0.05 |

IV-rtPA indicates intravenous recombinant tissue plasminogen activator; mRS; modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Table 7: Multiple imputation methods for deterioration.

|  |  |  |
| --- | --- | --- |
|  | **Odds ratio****(95% Confidence Interval)** | ***P* value** |
| Age (/y) | 1.04 (1.00–1.08) | 0.06 |
| Atrial fibrillation | 0.97 (0.56–1.70) | 0.92 |
| Hypertension | 1.28 (0.65–2.51) | 0.47 |
| Diabetes mellitus | 1.44 (0.85–2.42) | 0.17 |
| NIHSS (/1 point) | 1.05 (1.01–1.09) | < 0.05 |
| IV-rtPA therapy | 0.83 (0.49–1.42) | 0.50 |
| Successful reperfusion | 0.41 (0.24–0.69) | < 0.01 |
| PH2\* or SAH | 1.23 (0.48–3.11) | 0.67 |
| mRS score at 90 days (/1 point) | 0.87 (0.72–1.06) | 0.17 |

IV-rtPA indicates intravenous recombinant tissue plasminogen activator; mRS; modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma grade 2; and SAH, subarachnoid hemorrhage.

\*A grade of PH2 indicates hematoma with blood clots comprising more than one third of the infarcted area.

Supplemental Figure 1



Numbers of direct angioplasty, Merci Retrieval System, Penumbra System, and stent retriever in each year, and rates of successful reperfusion in each year.